Sam Brusco, Associate Editor10.02.23
Enable Injections has received U.S. Food and Drug Administration (FDA) approval of its enFuse injector for subcutaneous delivery of Apellis Pharmaceuticals’ EMPAVELI (pegcetacoplan) to treat adults with paroxysmal nocturnal hemoglobinuria (PNH).
The injector is compact and wearable, and according to Enable, streamlines self-administration with minimal disruption to patients’ daily lives. enFuse provides hands-free, hidden needle drug delivery of up to 25 mL to create simplicity and enable flexibility.
The approval of the EMPAVELI Injector will enhance the patient experience of administering a large volume (20 mL) of subcutaneous therapy," Enable Injections' chairman and CEO Michael D. Hooven told the press. "Enable's purpose is to redefine drug delivery for the benefit of patients. We are excited about achieving this milestone and are looking forward to growing enFuse partnerships to improve the patient experience around the world."
"The EMPAVELI Injector is the first purely mechanical, large-volume, on-body subcutaneous drug delivery device," added Matthew Huddleston, Enable Injections' chief technology officer and executive VP of business development. "The technology was designed while always keeping the patient at the forefront. Its simplicity empowers patients to confidently self-administer their therapy at home with greater mobility."
The injector is compact and wearable, and according to Enable, streamlines self-administration with minimal disruption to patients’ daily lives. enFuse provides hands-free, hidden needle drug delivery of up to 25 mL to create simplicity and enable flexibility.
The approval of the EMPAVELI Injector will enhance the patient experience of administering a large volume (20 mL) of subcutaneous therapy," Enable Injections' chairman and CEO Michael D. Hooven told the press. "Enable's purpose is to redefine drug delivery for the benefit of patients. We are excited about achieving this milestone and are looking forward to growing enFuse partnerships to improve the patient experience around the world."
"The EMPAVELI Injector is the first purely mechanical, large-volume, on-body subcutaneous drug delivery device," added Matthew Huddleston, Enable Injections' chief technology officer and executive VP of business development. "The technology was designed while always keeping the patient at the forefront. Its simplicity empowers patients to confidently self-administer their therapy at home with greater mobility."